The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the booster dose of Moderna, Inc.’s (MRNA) COVID-19 vaccine. The dose provided by the American pharmaceutical and biotechnology company can be administered at the 50 µg level to people aged 65 and above, adults (aged 18 to 64) who are at a high risk of severe COVID-19, and people (aged 18 to 64) with frequent occupational exposure to SARS-CoV-2, the company said. The recommendation followed the recent U.S. Food and Drug Administration's (FDA) emergency use authorization (EUA) for the booster dose, which is to be administered minimum after six months following primary vaccinations.
https://www.tipranks.com/news/modernas-covid-19-vaccine-booster-dose-recommended-by-acip?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Moderna Charts.